Texas Children’s Hospital Center for Vaccine Development (CVD)

Recombinant Protein COVID-19 Vaccine Technology

Since 2011, the BCM-Texas Children’s CVD has been developing recombinant protein coronavirus vaccines for SARS and MERS, and in 2020 developed the first recombinant protein COVID-19 through microbial fermentation in yeast.  The technology has been transferred to 4 entities to date: India (Biological E, CORBEVAX), Indonesia (BioFarma, CORONAVAC), Bangladesh (Incepta) and Botswana (ImmunityBio). In India and Indonesia, more than 100 million doses of these vaccines have been administered. CORBEVAX has also been authorized as an adult heterologous booster.  To date there are 8 scientific publications about laboratory development of the BCM-Texas Children’s CVD recombinant protein COVID-19 vaccine (in addition to 5 others on SARS/MERS (not shown), and 3 on the clinical trials see below):

Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
Whole Inactivated Virus and Protein-Based COVID-19 Vaccines
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1

The published results from the clinical trials performed by Biological E Ltd. can be found in the following peer-reviewed articles: 

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial
 Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
Safety, tolerability and immunogenicity of Biological E’s CORBEVAX vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study

Heterologous Booster Dose with
CORBEVAX following Primary Vaccination with
COVISHIELD Enhances Protection against SARS-CoV-2